Scott Kathleen D.'s Insider Trades & SAST Disclosures
Scott Kathleen D.'s most recent trade in Dermata Therapeutics Inc was a trade of 5,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Scott Kathleen D..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dermata Therapeutics Inc | Kathleen D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 176,700 | 176,700 | - | - | Stock option (right to buy) | |
| NKGen Biotech Inc | Kathleen D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2024 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| NKGen Biotech Inc | Kathleen D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2024 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 16 Oct 2024 | 12,500 | 4,949 | - | 16 | 200,000 | Common Stock |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2024 | 12,500 | 802,330 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 16 Oct 2024 | 12,500 | 17,449 | - | 1.5 | 18,750 | Common Stock |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2024 | 12,500 | 814,830 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 20 Aug 2024 | 12,500 | 25,699 | - | 1.5 | 18,750 | Common Stock |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 20 Aug 2024 | 12,500 | 13,199 | - | 16 | 200,000 | Common Stock |
| NKGen Biotech Inc | D. Scott Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Dermata Therapeutics Inc | Scott Kathleen D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Kathleen Scott D. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 200,000 | 200,000 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.24 per share. | 29 Nov 2022 | 8,250 | 8,250 | - | 6.2 | 51,506 | Common Stock |
| ARS Pharmaceuticals Inc | Kathleen D. Scott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 827,330 | 827,330 | - | - | Employee Stock Option (right to buy) | |
| Dermata Therapeutics Inc | Kathleen D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 9,960 | 15,786 | - | 0 | Common Stock | |
| Dermata Therapeutics Inc | Kathleen D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 5,826 | 5,826 | - | 0 | Common Stock | |
| Dermata Therapeutics Inc | Kathleen D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Dermata Therapeutics Inc | Kathleen D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 10,000 | 10,000 | - | - | Stock Option (right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges